AXD2 Stock Overview
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Heron Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.15 |
| 52 Week High | US$2.80 |
| 52 Week Low | US$0.51 |
| Beta | 1.71 |
| 1 Month Change | -13.59% |
| 3 Month Change | -1.38% |
| 1 Year Change | 3.37% |
| 3 Year Change | -84.51% |
| 5 Year Change | -85.43% |
| Change since IPO | -76.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXD2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.6% | 0.8% | -0.5% |
| 1Y | 3.4% | -21.0% | 2.5% |
Return vs Industry: AXD2 exceeded the German Biotechs industry which returned -19.8% over the past year.
Return vs Market: AXD2 exceeded the German Market which returned 1.8% over the past year.
Price Volatility
| AXD2 volatility | |
|---|---|
| AXD2 Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AXD2's share price has been volatile over the past 3 months.
Volatility Over Time: AXD2's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 126 | Craig Collard | www.herontx.com |
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Heron Therapeutics, Inc. Fundamentals Summary
| AXD2 fundamental statistics | |
|---|---|
| Market cap | €328.59m |
| Earnings (TTM) | -€103.06m |
| Revenue (TTM) | €118.43m |
3.0x
P/S Ratio-3.5x
P/E RatioIs AXD2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXD2 income statement (TTM) | |
|---|---|
| Revenue | US$127.04m |
| Cost of Revenue | US$117.00m |
| Gross Profit | US$10.04m |
| Other Expenses | US$120.60m |
| Earnings | -US$110.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 7.90% |
| Net Profit Margin | -87.02% |
| Debt/Equity Ratio | -511.4% |
How did AXD2 perform over the long term?
See historical performance and comparison